NCT02229799终止不适用
Protocol for Post Marketing Surveillance of Actilyse Vial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 265
- 主要终点
- Number of patients with clinically significant abnormal findings in physical examination
研究概览
简要总结
The objectives of this study are to review the safety and efficacy of Actilyse Vial (hereafter referred to as "Actilyse") in post-marketing use for treatment of acute ischemic stroke, through investigating followings;
- Unknown adverse events (especially serious adverse events)
- Frequency (Incidence) and trend of adverse events under the actual practice
- Factors on the safety profile of Actilyse
- Factors on the efficacy profile of Actilyse
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All in/out patients diagnosed as acute ischemic stroke
排除标准
- •Actilyse should not be administered to patients with high risk as follows:
- •Significant bleeding disorder at present or within the past 6 months, known hemorrhagic diathesis
- •Patients receiving oral anticoagulants, e.g. warfarin sodium (INR > 1.3)
- •Manifest bleeding or recent severe or dangerous bleeding
- •History or evidence or suspicion of intracranial hemorrhage including sub-arachnoid hemorrhage
- •Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- •Hemorrhagic retinopathy (e.g. in diabetes, vision disturbances may indicate hemorrhagic retinopathy) or other hemorrhagic ophthalmic conditions
- •Prolonged or traumatic cardiopulmonary resuscitation (> 2 minutes), obstetrical delivery, within the past 10 days, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture)
- •Severe uncontrolled arterial hypertension
- •Bacterial endocarditis or pericarditis
- •Acute pancreatitis
- •Documented ulcerative gastrointestinal disease within the past 3 months, oesophageal varices, arterial-aneurysms, or arterial/venous malformations
- •Neoplasm with increased bleeding risk
- •Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis
- •Hypersensitive to the active substance alteplase or to any of the excipients
- •In cases of acute myocardial infarction and acute pulmonary embolism, any history of stroke should be contraindicated.
- •In case that Actilyse is administered to acute ischaemic stroke, the followings should be contraindicated:
- •Symptoms of ischemic attack began more than 3 hours prior to infusion start or when time of symptom onset is unknown,
- •Symptoms of acute ischemic stroke that were either rapidly improving or only minor before start of infusion
- •Severe stroke as assessed clinically and/or by appropriate imaging techniques,
- •Seizure at onset of stroke
- •Evidence of intracranial hemorrhage (ICH) on the CT-scan
- •Symptoms suggestive of subarachnoid hemorrhage, even if CT-scan is normal
- •Administration of heparin within 48 hours preceding the onset of stroke with an elevated activated partial thromboplastin time (aPTT) at presentation
- •A combination of previous stroke and diabetes mellitus
- •Prior stroke or head trauma within the past 3 months
- •Platelet count of less than 100,000/mm3
- •Systolic blood pressure>185 mm Hg, or diastolic blood pressure>110 mm Hg, or aggressive management (IV medication) is necessary to reduce blood pressure to these limits
- •Blood glucose<50mg/dl or >400 mg/dl
- •Acute stroke patients between the age of ≤ 18 or ≥ 80 years
研究组 & 干预措施
Stroke patients
干预措施: Actilyse (Drug)
结局指标
主要结局
Number of patients with clinically significant abnormal findings in physical examination
时间窗: up to 30 days
Clinical effectiveness assessed by 30 days-mortality
时间窗: 30 days
Number of patients with adverse events
时间窗: up to 30 days
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in KoreaHepatitis C VirusNCT02907996Gilead Sciences2,033
尚未招募
不适用
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With IruplinalkibNSCLCNCT06644495Qilu Pharmaceutical Co., Ltd.1,000
已完成
不适用
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic ArthritisArthritis, PsoriaticNCT00938015Pfizer303
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%Conjunctivitis, Seasonal AllergicConjunctivitis, Giant PapillaryInflammationNCT01437982Bausch & Lomb Incorporated140
已完成
不适用
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South KoreaEssential HypertensionNCT04470830Celltrion Pharm, Inc.718